Persistent Midlife Loneliness May Up Later Dementia, AD Risk
TUESDAY, April 6, 2021 -- Persistent loneliness in midlife is an independent risk factor for later dementia and Alzheimer disease, according to a study published in Alzheimer's & Dementia.
Samia C. Akhter-Khan, from Humboldt University of Berlin, and colleagues assessed loneliness in cognitively normal middle-aged adults participating in the Framingham Heart Study using one item from the Center for Epidemiologic Studies Depression Scale and then tracked future Alzheimer disease and dementia.
The researchers found that after adjusting for demographics, social network, physical health, and apolipoprotein E ε4, persistent loneliness was associated with a higher risk for dementia onset (hazard ratio, 1.91) compared with no loneliness. Transient loneliness was associated with a lower risk for dementia onset (hazard ratio, 0.34) compared with no loneliness. The investigators observed similar associations for Alzheimer disease risk and loneliness.
"Our findings are in line with evolutionary theories stating that loneliness could be both adaptive and maladaptive for humans, depending on its persistency," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Read this next
THURSDAY, April 22, 2021 -- Individuals who have clinically recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and continue to test positive for...
WEDNESDAY, April 21, 2021 -- Specific cognitive deficits in childhood are distinctively associated with different mental health disorders, like borderline personality disorder,...
WEDNESDAY, April 21, 2021 -- Sex disparities in COVID-19 mortality do not hold across racial groups, according to a study published online April 5 in the Journal of General...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.